Efficacy results for EPKINLY (N=148)1,2

Learn more about the EPCORE™ NHL-1 study

61% of patients had a response and 38% of patients had a CR

61% of patients had a response, 38% of patients had a complete response, and 23% had a partial response.

Efficacy results were determined by Lugano criteria (2014) as assessed by Independent Review Committee (IRC).

Duration of response1,2

Median duration of overall response was 15.6 months, estimated 63% responding at 9 months. Median duration of complete response was not reached, 87% still responding at 9 months.
Median duration of overall response was 15.6 months, estimated 63% responding at 9 months. Median duration of complete response was not reached, 87% still responding at 9 months.

Among responders, the median follow-up for DOR was 9.8 months (range: 0-17.3 months).1

Among complete responders, the median follow-up for DOCR was 9.7 months (range: 8.3-12.1 months).2

Time to response1,2

  • Median time to response was 1.4 months (median; range: 1-8.4 months)1
  • Median time to CR was 2.6 months (range: 1.2-10.2 months)2

*Based on Kaplan-Meier estimate.

ORR and CR rates observed in select prespecified subgroups2

CAR T naïve had a 67% overall response rate, 41% had a complete response, and 26% had a partial response.
Prior CAR T exposed had a 52% overall response rate, 33% had a complete response, and 19% had a partial response.
CAR T refractory had a 42% overall response rate, 26% had a complete response, and 16% had a partial response.
Primary refractory had a 52% overall response rate, 28% had a complete response, and 24% had a partial response.

Data Limitation: Study was not powered to evaluate these prespecified subgroups. Data are exploratory and descriptive in nature.

CAR T=chimeric antigen receptor T cell; CI=confidence interval; CR=complete response; DOR=duration of response; NHL=non-Hodgkin lymphoma; ORR=overall response rate; PR=partial response.

" "

Adverse reactions occurred with EPKINLY

View now
" "

Contact a representative to speak in more detail about efficacy for EPKINLY

Get in touch today